Does nimodipine prevent vasospasm?
Nimodipine is a dihydropyridine that blocks calcium influx through the L-type calcium channels. It is the most rigorously studied and only drug approved by the US Food and Drug Administration for use in treatment of vasospasm. Nimodipine is administered in a dose of 60 mg every 4 hours for 14–21 days after SAH.Click to see…
Nimodipine is a dihydropyridine that blocks calcium influx through the L-type calcium channels. It is the most rigorously studied and only drug approved by the US Food and Drug Administration for use in treatment of vasospasm. Nimodipine is administered in a dose of 60 mg every 4 hours for 14–21 days after SAH.Click to see full answer. Also asked, how do you prevent vasospasm?In addition to angioplasty, vasodilating agents such as papaverine or verapamil, can be infused directly (intra-arterially) to relieve the spasm. Hypertension, hypervolemia, and hemodilution (triple-H therapy) is often utilized to prevent and treat cerebral vasospasm after aneurysmal subarachnoid hemorrhage (SAH).Secondly, why is nimodipine used for SAH? Oral nimodipine is the most studied calcium channel blocker for prevention of vasospasm after SAH. Calcium channel blockers have been shown to reduce the incidence of ischemic neurologic deficits, and nimodipine has been shown to improve overall outcome within 3 months of aneurysmal SAH. Moreover, what medication is used to decrease vasospasm? Other medications used to reduce the occurrence and severity of vasospasm and ultimately ischemia include L-type calcium channel blockers (notably nimodipine, as well as verapamil, diltiazem, nifedipine) and beta-receptor antagonists (more commonly known as beta blockers or β-blockers) such as propranolol.Which calcium channel blocker is typically used to prevent vasospasm in stroke patients?Oral nimodipine is recommended in the prevention/treatment of cerebral vasospasm following subarachnoid hemorrhage (SAH). CCBs, particularly nimodipine, may be of some benefit in vascular or mixed degenerative and vascular dementia or, taking into account subtypes, more selectively in subcortical vascular dementia.
